Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis (MITRAS)

Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with oncological lesions in need of non-surgical therapy, patients with cardiovascular atherosclerosis, syndrome with abnormal immune activation and sarcoïdosis.

Study Overview

• Status: Recruiting
• Conditions: Cancer; Carotid Stenosis; Non Hodgkin Lymphoma; Sarcoidosis; Cardiac Sarcoidosis; Hodgkin Lymphoma, Adult; Atherosclerosis of Artery; HLH; Solid Malignancy Located in the Head and Neck
• Intervention / Treatment: Drug: 68GaNOTA-Anti-MMR-VHH2

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: UZ BRUSSEL; Phone Number: +3224776013; Email: nucgmail@uzbrussel.be

Study Locations

• Belgium
  • Brussel
    • Brussels, Brussel, Belgium, 1090
      • Recruiting
      • UZ Brussel
      • Contact: UZ BRUSSEL; Phone Number: +3224776013; Email: nucgmail@uzbrussel.be
      • Principal Investigator: Tony Lahoutte, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

COHORT SPECIFIC INCLUSION CRITERIA:

• COHORT 1:

  - Patients who have given informed consent

  - Patients at least 18 years old

  - Patients with : A) biopsy-proven solid malignancy located in the head and neck, independent of tumour stage or pathological subtype, or B) suspected malignancy in the head and neck, planned for biopsy

  • In order to minimize partial volume effect, the diameter of at least 1 tumour lesion should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions.
  • Patients who already participated in the trial and who are diagnosed with progressive or recurrent disease can be re-included if all inclusion criteria and none of the exclusion criteria apply.

• COHORT 2:

  • Patients who have given informed consent
  • Patients at least 18 years old
  • Patient with a biopsy proven local, locally advanced or metastatic malignancy with a solid component that is at least ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions.
  • The patient is planned for immune checkpoint inhibition treatment, either or not combined with other systemic therapies.
  • Patients who already participated in the trial and who are diagnosed with progressive or recurrent disease can be re-included if all inclusion criteria and none of the exclusion criteria apply

• COHORT 3:

  • Patients who have given informed consent
  • Patients at least 18 years old
  • Patients planned for the surgical removal of an atherosclerotic plaque of the carotid artery, consisting of endarterectomy.

• COHORT 4:

  • Patients who have given informed consent
  • Patients at least 18 years old
  • Patient with a biopsy-proven Hodgkin or non-Hodgkin lymphoma
  • At time of inclusion, the patient presents with at least 1 lymphoma lesion of which the diameter should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions.
  • Diagnostic tissue sample is available for immunohistochemistry analysis, that was obtained < 3 months prior to patient inclusion.
  • 18F-FDG-PET/CT has been performed < 3 months prior to patient inclusion
  • The patients are eligible for systemic treatment, radiotherapy or a combination of both.

• COHORT 5:

  • Patients who have given informed consent
  • Patients at least 18 years old
  • Patients with suspicion of HLH, based on either a previous bone marrow sample showing hemofagocytis or based on the presence of at least 3 risk criteria as follows :
  • Fever ≥ 38,5°C
  • Splenomegaly
  • Bicytopenia, with at least 2 of the 3 following parameters:
  • Hb < 9 g/dl and/or
  • Platelets < 100 000/ml and/or
  • Neutrophils < 1000/ml
  • Hypertriglyceridemia (fasting > 265 mg/dl)µ
  • Ferritin > 500 ng/ml

• COHORT 6:

  • Patients who have given informed consent
  • Patients at least 18 years old
  • Patients with :

A) Endomyocardial biopsy-proven cardiac sarcoidosis (CS) or B) suspected cardiac sarcoidosis based on the 2014 Hearth Rythm Society Expert Consensus Statement on the Diagnosis and Management of Arrhytmias Associated with Cardiac Sarcoidosis. At least one of the following criteria should be met :

• Steroid +/- Immunosuppressant responsive cardiomyopathy or heart block
• Unexplained reduced left ventricular ejection fraction (LVEF) <40%
• Unexplained sustained (spontaneous or induced) ventricular tachycardia (VT)
• Mobitz type II 2nd-degree heart block or 3rd-degree heart block
• Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)
• Late Gadolinium Enhancement on Cardiovascular Magnetic Resonance (in a pattern consistent with CS)
• Positive gallium uptake (in a pattern consistent with CS)
• Histological Diagnosis from Myocardial Tissue

• Patients already included in cohort 7 with progression to cardiac sarcoidosis

  *COHORT 7:

• Patients who have given informed consent
• Patients at least 18 years old
• Patients with biopsy-proven sarcoidosis

GENERAL EXCLUSION CRITERIA:

• Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher.
• Pregnant patients.
• Breast feeding patients.
• Patients with any serious active infection.
• Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical.
• Patients who cannot communicate reliably with the investigator.
• Patients who are unlikely to cooperate with the requirements of the study.
• Patients who are unwilling and/or unable to give informed consent.
• Patients at increased risk of death from a pre-existing concurrent illness.
• When a patient exhibits symptoms correlated with SARS-CoV-2, the patient should be tested using the standard of care testing protocol, prior to inclusion. When the test results indicate an active SARS-CoV-2-infection, the patient is excluded for this trial.

COHORT SPECIFIC EXCLUSION CRITERIA

• COHORT 2

  • Patients with a biopsy-proven Hodgkin or non-Hodgkin lymphoma
  • Patients diagnosed with any malignancy of the head and neck. These patients can be included into Cohort I.
• COHORT 7 - Patients eligible for cohort 6

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Cancer, lymphoma, carotid plaque, patients suspected for HLH, sarcoidosis; Cohort 1: Patients diagnosed with pathology malignancies of the head and neck Cohort 2: Patients diagnosed with any malignancy with a solid component Cohort 3: Patients diagnosed with carotid plaque, planned for SOC carotid endarterectomy Cohort 4: Patients with a biopsy-proven Hodgkin or non-Hodgkin lymphoma Cohort 5: Patients suspected for HLH, planned for (SOC) bone marrow in case it is not done before Cohort 6 : Patients with endomyocardial biopsy proven or suspected cardiac sarcoïdosis Cohort 7 : Patients with biopsy-proven sarcoïdosis

Drug: 68GaNOTA-Anti-MMR-VHH2; All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy. For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP.; Other Names: MMR-PET/CT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 before start of treatment in solid cancer lesions with time to treatment failure after systemic treatment with immune checkpoint inhibition, either or not combined with other systemic therapies. (cohort 2)	Uptake will be measured in cancer lesions on PET/CT 1. Treatment response will be evaluated by assessing time to treatment failure and by assessment of status of patients for treatment failure (Y/N) at 6 months and 12 months after start of treatment	up to 5 years
Correlation of IMP uptake before start of treatment in malignant lesions of the head and neck with either treatment response during or after radiotherapy or systemic treatment, or with immunohistological MMR-staining in patients with surgical treatment	Uptake will be measured in cancer lesions on PET/CT 1. Treatment response will be evaluated by assessing time to treatment failure and by assessment of status of patients for treatment failure (Y/N) at 6 and 12 months after start of treatment or immunological MMR staining	up to 5 years
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in atherosclerotic carotid plaques before surgery with the immunohistological MMR-staining of the excised atherosclerotic carotid plaque.(cohort 3)	Uptake in excised atherosclerotic plaque on PET/CT 1. Immunohistological MMR staining of excised atherosclerotic plaque, scored visually by interpreter	Resection of lesion up to 21 days after PET/CT
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in lymphoma-related lesions before start of treatment in Hodgkin and non-Hodgkin lymphoma patients (cohort 4).	Uptake will be measured in lymphoma-related lesions on MMR-PET/CT 1	up to 5 years
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in central bone on PET/CT with the presence of hemophagocytosis in bone marrow samples, and the presence of clinical risk factors (cohort 5).	Uptake in bone marrow on MMR-PET/CT 1. Bone marrow aspirate or trephine biopsy, scored individually by interpreter. Results of additional blood sample analysis to determine clinical risk factor	up to 5 years
To investigate the uptake of 68GaNOTA-Anti-MMR-VHH2 in cardiac sarcoidosis on PET/CT in patients with endomyocardial biopsy proven or suspected cardiac sarcoidosis (cohort 6)	Uptake in lesions with known or suspected cardiac sarcoidosis on MMR-PET/CT on PET/CT1	up to 5 years
To investigate the uptake of 68GaNOTA-Anti-MMR-VHH2 in sarcoidosis on PET/CT in patients with biopsy-proven sarcoidosis (cohort 7)	Uptake in lesions involved with sarcoidosis on MMR-PET/CT	up to 5 years

Collaborators and Investigators

• Sponsor: Universitair Ziekenhuis Brussel
• Investigators: Principal Investigator: Tony Lahoutte, MD, Universitair Ziekenhuis Brussel

Study record dates

Study Major Dates

• Study Start (Actual): January 26, 2021
• Primary Completion (Estimated): January 26, 2025
• Study Completion (Estimated): January 26, 2025

Study Registration Dates

• First Submitted: February 12, 2021
• First Submitted That Met QC Criteria: February 12, 2021
• First Posted (Actual): February 17, 2021

Study Record Updates

• Last Update Posted (Estimated): November 20, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Immune System Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Hypersensitivity; Carotid Artery Diseases; Hypersensitivity, Delayed; Lymphoma; Hodgkin Disease; Carotid Stenosis; Atherosclerosis; Sarcoidosis
• Other Study ID Numbers: UZBRU_VHH2_2; 2020-002483-31 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No